Integra LifeSciences Q2 FY26 GAAP EPS turns to profit at $0.06; revenue rises 0.8% to $418.8 million

• Integra LifeSciences posted Q2 revenue of USD 418.8 million, up 0.8% from a year earlier.
• GAAP net income swung to USD 4.5 million; GAAP diluted EPS was USD 0.06.
• GAAP gross margin widened 2.1 percentage points to 52.5%.
• Adjusted EBITDA rose to USD 78.4 million, lifting margin to 18.7%.
• Started production at the Braintree facility; remains on track for a planned Q4 relaunch of SurgiMend.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Integra LifeSciences Holdings Corporation published the original content used to generate this news brief on July 29, 2026, and is solely responsible for the information contained therein.